Elismetrep
Unknown / undisclosed
Also known as MT-8554
Evidence outlook · registrational
Migraine: registrational readout pending
Its supporting mid-stage studies have completed. Registrational readout expected around 2027-02.
Latest reported trial: NCT06848075 · Phase 2 · missed primary endpoint · grade pending
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT07645924 NCT07645924 · Migraine Registry: NCT07645924 | 3 | Pain freedom at 2 hours post-dose (Two hours post-dose); Freedom from most bothersome symptoms (MBS) at 2 hours post-dose (Two hours post-dose) 2027-02 | In progress: results expected 1 Feb 2027 | not yet graded | link ↗ |
View 3 more trials
NCT07674654 NCT07674654 · Migraine Registry: NCT07674654 | 3 | Proportion of participants with at least one treatment-emergent adverse event (TEAE) (Through study completion, an average of 1 year); Proportion of participants with at least one treatment-emergent serious adverse event (SAE) (Through study completion, an average of 1 year); Proportion of participants with TEAEs leading to study drug discontinuation (Through study completion, an average of 1 year); Proportion of participants with TEAEs that occur in at least 5% of treated participants in either treatment arm (Through study completion, an average of 1 year) 2028-06 | In progress: results expected 1 Jun 2028 | not yet graded | link ↗ |
NCT06848075 NCT06848075 · Migraine This Phase 2b dose-finding trial randomized 431 adults with migraine to one of four elismetrep doses (2 to 20 mg) or placebo for a single attack, under triple masking. The single primary endpoint was freedom from pain 2 hours after the dose. The highest dose gave a numerically higher rate than placebo (17.6% vs 9.1%), but no dose was statistically significant (best one-sided p=0.065), so the primary endpoint was missed. The company reports benefits on secondary endpoints. Source: the CT.gov posted results. Registry: NCT06848075 | 2 | Pain Freedom (2 hours post-dose) 2025-08-04 | Pain freedom at 2 hours post-dose (single registered primary), mITT: elismetrep 20 mg 9/51 (17.6%) vs placebo 9/99 (9.1%), risk difference 8.54 points (90% CI -1.45 to 18.52), one-sided p=0.0650; 2 mg, 5 mg and 10 mg one-sided p=0.40, 0.42 and 0.38. No dose reached significance; no multiplicity adjustment (CT.gov posted results). | not yet graded | link ↗ |
NCT07816367 NCT07816367 · Migraine Registry: NCT07816367 | 3 | Pain freedom at 2 hours post-dose (Two hours post-dose); Freedom from most bothersome symptoms (MBS) at 2 hours post-dose (Two hours post-dose) 2027-10 | In progress: results expected 1 Oct 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Migraine: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Elismetrep: this drug | Phase 3 | — | TRPM8 | not yet graded | No reviewed efficacy summary in this indication | |
| Aspirin / Acetaminophen / Caffeine (Excedrin Migraine) | Approved | — | Nonsteroidal Anti-inflammatory Drug, Adenosine receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Atogepant (Qulipta) | Approved | Small molecule | CGRP receptor | Reliable signal | NCT03777059: Change From Baseline in Mean Monthly Migraine Days Across the 12-Week Treatment Period (Baseline (Day -28 to Day -1) to Week 12): Placebo -2.48 migraine days per month (Standard Error 0.21) | Atogepant 10 mg -3.69 migraine days per month (Standard Error 0.21) | Atogepant 30 mg -3.86 migraine days per month (Standard Error 0.206) | Atogepant 60 mg -4.2 migraine days per month (Standard Error 0.206) NCT02848326: Change From Baseline in Mean Monthly Migraine Days (Migraine/Probable Migraine Headache Days) Across the 12-Week Treatment Period (Baseline (First 28 Days of Screening/Baseline Period) to Week 12): Placebo -2.85 migraine days per month (Standard Error 0.23) | Atogepant 10 mg QD -4 migraine days per month (Standard Error 0.32) | Atogepant 30 mg QD -3.76 migraine days per month (Standard Error 0.23) | Atogepant 60 mg QD -3.55 migraine days per month (Standard Error 0.23) | Atogepant 30 mg BID -4.23 migraine days per month (Standard Error 0.35) | Atogepant 60 mg BID -4.14 migraine days per month (Standard Error 0.33) | |
| Celecoxib (Elyxyb) | Approved | Small molecule | COX-2 | Partial signal | No reviewed efficacy summary in this indication | |
| Diclofenac Potassium (Cambia) | Approved | Small molecule | Nonsteroidal Anti-inflammatory Drug | not yet graded | No reviewed efficacy summary in this indication | |
| Dihydroergotamine (Atzumi) | Approved | Small molecule | 5-HT1D receptor | Partial signal | NCT04940390: Co-primary endpoints at 2 hours, STS101 5.2 mg (n=716) vs placebo (n=708), mITT: freedom from pain 146/716 (20.4%) vs 124/708 (17.5%); freedom from most bothersome symptom 265/716 (37.0%) vs 230/708 (32.5%). The sponsor states the differences did not reach statistical significance; no p-values are reported. missed NCT03901482: Co-primary endpoints at 2 hours, STS101 3.9 mg (n=354) and 5.2 mg (n=353) vs placebo (n=358), mITT: freedom from pain 69/354 (19.5%) and 68/353 (19.3%) vs 53/358 (14.8%); freedom from most bothersome symptom 133/354 (37.6%) and 139/353 (39.4%) vs 119/358 (33.2%). The sponsor states neither dose was statistically significant on either co-primary endpoint; no p-values are reported. missed | |
| Dihydroergotamine Mesylate (Brekiya) | Approved | Small molecule | 5-HT1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Dihydroergotamine Mesylate (D.H.E. 45) | ApprovedUS marketing discontinued | Small molecule | 5-HT1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Dihydroergotamine Mesylate (Migranal) | Approved | Small molecule | 5-HT1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Divalproex Sodium (Depakote ER) | Approved | Small molecule | GABAergic neurotransmission | not yet graded | No reviewed efficacy summary in this indication | |
| Divalproex Sodium (Depakote) | Approved | Small molecule | GABAergic neurotransmission | not yet graded | No reviewed efficacy summary in this indication | |
| Eletriptan (Relpax) | Approved | Small molecule | 5-HT1B/1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Eptinezumab (Vyepti) | Approved | Monoclonal antibody | CGRP ligand | Reliable signal | NCT02974153: Change From Baseline in Monthly Migraine Days (Week 1-12): 300 mg ALD403 -8.2 Migraine Days (range -23 to 11) | 100 mg ALD403 -7.7 Migraine Days (range -22 to 10) | Placebo -5.6 Migraine Days (range -25 to 9) NCT02559895: Change From Baseline in Monthly Migraine Days (Weeks 1-12) (Week 1-12): 300 mg ALD403 -4.3 Migraine Days (Standard Deviation 3.42) | 100 mg ALD403 -3.9 Migraine Days (Standard Deviation 3.23) | 30 mg ALD403 -4.1 Migraine Days (Standard Deviation 3.22) | Placebo -3.1 Migraine Days (Standard Deviation 3.7) | |
| Erenumab (Aimovig) | Approved | Monoclonal antibody | CGRP receptor | Reliable signal | NCT03867201: Change From Baseline in Monthly Migraine Days During the Last 4 Weeks of the 12-week Treatment Period (baseline (4 weeks period prior to start of study drug), week 9 to 12): Erenumab 70 mg -8.19 days (Standard Error 0.46) | Placebo -6.62 days (Standard Error 0.45) NCT02456740: Change From Baseline in Mean Monthly Migraine Days to the Last 3 Months of the Double-blind Treatment Period (4-week baseline phase and the last 3 months (months 4, 5, and 6) of the 24-week double-blind treatment phase): Placebo -1.83 migraine days / month (Standard Error 0.18) | Erenumab 70 mg QM -3.23 migraine days / month (Standard Error 0.18) | Erenumab 140 mg QM -3.67 migraine days / month (Standard Error 0.18) | |
| Ergotamine / Caffeine (Cafergot) | ApprovedUS marketing discontinued | Small molecule | Alpha-adrenergic receptor, Adenosine receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Fremanezumab (Ajovy) | Approved | Monoclonal antibody | CGRP ligand | Partial signal | NCT04458857: Change in monthly migraine days over 12 weeks: fremanezumab -2.5 vs placebo -1.4; LS mean difference -1.0 (95% CI -1.90 to -0.16), p=0.0210 (n=123 and 111) (CT.gov posted results). NCT02621931: Change in monthly headache days of at least moderate severity over 12 weeks (median): fremanezumab 675 mg quarterly -4.2 (n=375) and 675/225/225 mg monthly -4.5 (n=375) vs placebo -2.5 (n=371); LS mean difference from placebo -1.8 (95% CI -2.46 to -1.15) and -2.1 (95% CI -2.76 to -1.45), both p < 0.0001 (Wilcoxon) (CT.gov posted results). | |
| Frovatriptan (Frova) | ApprovedUS marketing discontinued | Small molecule | 5-HT1B/1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Galcanezumab (Emgality) | Approved | Monoclonal antibody | CGRP ligand | Reliable signal | NCT03963232: Change in monthly migraine headache days over 3 months, LS mean -3.81 (galcanezumab 120 mg) vs -1.99 (placebo); difference -1.82 days (95% CI -2.32 to -1.32), p<.0001. NCT03559257: Change in monthly migraine headache days over months 1 to 3 (treatment-resistant migraine), LS mean -4.14 (galcanezumab 120 mg) vs -1.02 (placebo); difference -3.12 days (95% CI -3.92 to -2.32), p<0.0001. | |
| Ibuprofen (Advil Migraine) | Approved | Small molecule | Nonsteroidal Anti-inflammatory Drug | not yet graded | No reviewed efficacy summary in this indication | |
| Meloxicam / Rizatriptan (Symbravo) | Approved | Small molecule | 5-HT1B/1D receptor, Nonsteroidal Anti-inflammatory Drug | Reliable signal | Featured results are safety only in this race | |
| Naratriptan (Amerge) | ApprovedUS marketing discontinued | Small molecule | 5-HT1B/1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| onabotulinumtoxinA (Botox) | Approved | Biologic (subtype unspecified) | Acetylcholine Release Inhibitor, acetylcholine release | not yet graded | No reviewed efficacy summary in this indication | |
| Propranolol (Inderal LA) | Approved | Small molecule | Beta-1/beta-2 adrenergic receptors | not yet graded | No reviewed efficacy summary in this indication | |
| Rimegepant (Nurtec ODT) | Approved | Small molecule | CGRP receptor | Reliable signal | NCT05810038: Mean Change From the Observation Phase (OP) in Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12) (OP (screening of 4 weeks prior to randomization), DBT phase (Weeks 1 to 12)): DBT Rimegepant -3.64 Migraine days per month (Standard Error 0.14) | DBT Placebo -2.63 Migraine days per month (Standard Error 0.14) NCT05399485: Mean Change From Baseline in Number of Migraine Days Per Month From Week 9 to 12 of the Double-Blind Treatment (DBT) Phase (Baseline, Week 9 to Week 12 of the DBT phase): Rimegepant -2.4 Days/month (95% CI -2.93 to -1.96) | Placebo -1.4 Days/month (95% CI -1.87 to -0.91) | |
| Rizatriptan (Maxalt) | Approved | Small molecule | 5-HT1B/1D receptor | Partial signal | Featured results are non-efficacy only in this race | |
| Rizatriptan (RizaFilm) | Approved | Small molecule | 5-HT1B/1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Sumatriptan (Onzetra Xsail) | ApprovedUS marketing discontinued | Small molecule | 5-HT1B/1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Sumatriptan (Tosymra) | Approved | Small molecule | 5-HT1B/1D receptor | Weak signal | Featured results are safety only in this race | |
| Sumatriptan Succinate (Sumavel DosePro) | ApprovedUS marketing discontinued | Small molecule | 5-HT1B/1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Sumatriptan Succinate (Zembrace SymTouch) | Approved | Small molecule | 5-HT1B/1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Sumatriptan Succinate Injection (Imitrex) | Approved | Small molecule | 5-HT1B/1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Sumatriptan Succinate Nasal Spray (Imitrex) | Approved | Small molecule | 5-HT1B/1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Sumatriptan Succinate Tablets (Imitrex) | Approved | Small molecule | 5-HT1B/1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Sumatriptan / Naproxen Sodium (Treximet) | Approved | Small molecule | 5-HT1B/1D receptor, Nonsteroidal Anti-inflammatory Drug | Weak signal | No reviewed efficacy summary in this indication | |
| Topiramate (Eprontia) | Approved | Small molecule | Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase | not yet graded | No reviewed efficacy summary in this indication | |
| Topiramate (Qudexy XR) | Approved | Small molecule | Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase | not yet graded | No reviewed efficacy summary in this indication | |
| Topiramate (Topamax Sprinkle) | Approved | Small molecule | Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase | not yet graded | No reviewed efficacy summary in this indication | |
| Topiramate (Topamax) | Approved | Small molecule | Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase | Partial signal | NCT00236509: Primary endpoint, change in mean 4-week migraine frequency (baseline to double-blind phase, ITT n=469): -1.3, -2.1 and -2.2 with topiramate 50, 100 and 200 mg/day vs -0.8 with placebo; 100 and 200 mg/day vs placebo p<0.001 (TOPAMAX label, Study 11 = TOPMAT-MIGR-001). | |
| Topiramate (Trokendi XR) | Approved | Small molecule | Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase | not yet graded | No reviewed efficacy summary in this indication | |
| Ubrogepant (Ubrelvy) | Approved | Small molecule | CGRP receptor | Reliable signal | NCT04492020: Percentage of Participants Reporting Absence of Headache of Moderate/Severe Intensity Within 24 Hours Post-dose (24 hours after taking double-blind study intervention during the prodrome): Placebo 121 Participants | Ubrogepant 100 mg 190 Participants | |
| Zavegepant (Zavzpret) | Approved | Small molecule | CGRP receptor | Reliable signal | No reviewed efficacy summary in this indication | |
| Zolmitriptan (Zomig Nasal Spray) | Approved | Small molecule | 5-HT1B/1D receptors | not yet graded | No reviewed efficacy summary in this indication | |
| Almotriptan (Axert) | US approval withdrawn | Small molecule | 5-HT1B/1D receptor | Weak signal | No reviewed efficacy summary in this indication | |
| IncobotulinumtoxinA (Xeomin) | Phase 3 | Protein / enzyme therapeutic | acetylcholine release | not yet graded | No reviewed efficacy summary in this indication | |
| Rizatriptan / Naproxen | Phase 3 | Small molecule | 5-HT1B/1D receptor, Nonsteroidal Anti-inflammatory Drug | not yet graded | No reviewed efficacy summary in this indication | |
| Naltrexone / Acetaminophen (ALLOD-2) | Phase 2/3 | — | Opioid receptor | not yet graded | No reviewed efficacy summary in this indication | |
| BHV-2100 | Phase 2 | — | TRPM3 | not yet graded | No reviewed efficacy summary in this indication | |
| EVO756 | Phase 2 | Small molecule | MRGPRX2 | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-2002 | —(overall) | Undisclosed | PAR-2 | not yet graded | No reviewed efficacy summary in this indication | |
| Dihydroergotamine Mesylate / Dipyrone / Caffeine (Cefaliv) | —(overall) | — | 5-HT1D receptor, Adenosine receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Dipyrone / Isometheptene Mucate / Caffeine (Neosaldina) | —(overall) | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Lasmiditan (Reyvow) | Discontinued | Small molecule | 5-HT1F receptor | Reliable signal | No reviewed efficacy summary in this indication | |
| Propranolol (Inderal) | Discontinued | Small molecule | Beta-1/beta-2 adrenergic receptors | not yet graded | No reviewed efficacy summary in this indication | |
| Sumatriptan Succinate (Zecuity) | Discontinued | Small molecule | 5-HT1B/1D receptor | Partial signal | Featured results are non-efficacy and safety only in this race | |
| Sumatriptan Succinate Auto-Injector (Alsuma) | Discontinued | Small molecule | 5-HT1B/1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Zolmitriptan (Zomig) | Discontinued | Small molecule | 5-HT1B/1D receptors | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Elismetrep to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.